Related Experiment Video
Updated: Jan 30, 2026

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
Medication Discontinuation in the IMPROVE-IT Trial
Ann Marie Navar1,2, Matthew T Roe1, Jennifer A White1
1Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (A.M.N., M.T.R., J.A.W., Y.L., L.K.N., M.A.B.).
Insights
Premature discontinuation of cholesterol-lowering drugs reduces their effectiveness. The IMPROVE-IT trial found that adding ezetimibe to simvastatin did not increase discontinuation rates, but patient factors influenced adherence.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Cholesterol-lowering medications are vital for reducing recurrent cardiovascular events.
- Premature discontinuation of these medications significantly limits their therapeutic effectiveness.
- Systematic reporting of discontinuation rates in lipid-lowering trials remains limited.
Purpose of the Study:
- To evaluate medication discontinuation rates and predictors within the IMPROVE-IT trial.
- To compare discontinuation between placebo+simvastatin and ezetimibe+simvastatin treatment arms.
- To analyze the impact of patient-level and regional factors on medication adherence.
Main Methods:
- Longitudinal evaluation of medication discontinuation from randomization to study end (median 71.9 months).
- Kaplan-Meier (KM) analysis of discontinuation rates at 30 days, 1 year, and 7 years.
- Cox proportional hazards modeling to identify predictors of discontinuation.
Main Results:
- Overall, 46.7% of subjects discontinued study medication, with a 7-year KM rate of 50.9%.
- Discontinuation risk was highest early but stabilized to approximately 8% per year after year 1.
- Higher discontinuation was observed with placebo+simvastatin versus ezetimibe+simvastatin (52.0% vs. 49.8%) and in the United States (57.4% at 7 years).
- Predictors of higher discontinuation included smoking, prior revascularization, hypertension, unstable angina, female sex, nonwhite race, and US location.
Conclusions:
- While discontinuation risk decreases over time, most occurred after the first year due to prolonged follow-up.
- Adding ezetimibe to statin therapy did not elevate the risk of medication discontinuation.
- Trial design and analysis should account for geographic variations and patient-specific factors influencing adherence.
Background:
Although cholesterol-lowering medications can reduce the risk of recurrent cardiovascular events, premature discontinuation limits effectiveness. Discontinuation rates have not been systematically reported for lipid-lowering trials.
Methods And Results:
We evaluated medication discontinuation in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), which evaluated placebo+simvastatin versus ezetimibe+simvastatin in patients hospitalized with the acute coronary syndrome and followed longitudinally postdischarge. Reasons for discontinuation were evaluated from randomization through study end (median 71.9 [interquartile range 51.8-85.8] months). Kaplan-Meier (KM) discontinuation rates were evaluated at 30 days, 1 year, and through year 7, and compared by treatment arm and region, with Cox proportional hazards modeling used to evaluate predictors of discontinuation. Overall, 46.7% of subjects discontinued study medication (KM rate by study end 50.9% [95% CI, 50.1%-51.7%]). The risk of discontinuation was highest early in the trial but decreased with increasing time, with a terminal KM rate per 100 person-years of 8.4 (8.2-8.6) from years 1 to 7. Discontinuation was higher in the placebo+simvastatin versus ezetimibe+simvastatin arm (KM rate 52.0% versus 49.8%, P=0.049) and was highest in the United States (7-year KM rate 57.4%). In multivariable modeling, smoking, prior revascularization, hypertension, unstable angina, female sex, nonwhite race, and US location were associated with higher discontinuation rates.
Conclusions:
Although discontinuation was highest early and stabilized to 8% per year, because of prolonged follow-up, most discontinuation occurred after year 1. Adding ezetimibe to statin therapy did not increase discontinuation risk. Geographic differences and patient-level factors should be considered in trial design and analysis.
Clinical Trial Registration:
URL: https://www.clinicaltrials.gov . Unique identifier: NCT00202878.
Related Concept Videos
Limits with Oscillating Discontinuities
Improper Integrals: Discontinuous Integrands
Clinical Trials: Overview
Trial and Error and Algorithm
Clinical Trials
There are four phases in a clinical trial. A phase one...
Inhaled Medications

